Syncom Formulations (India) Ltd. (SYNCOMF): Syncom Formulations Share Price Rises 10.79% Today

Syncom Formulations Share Price Today stood at Rs 14.89, up 10.79%, taking market capitalisation to Rs 1,263.36 crore and placing the stock among today’s notable gainers.

Syncom Formulations Share Price was in focus on 10 August 2026 after the stock climbed to Rs 14.89, up Rs 1.45 or 10.79% from the previous close of Rs 13.44. With market capitalisation at Rs 1,263.36 crore, the company sits in the Small Cap category, and this move was large enough to qualify under the workflow’s price rise screen for that segment. For investors tracking Syncom Formulations Share Price Today, the verified data confirms a strong single-session gain, although the supplied dataset does not establish a company-specific catalyst behind the move.

The session’s range was wide but directional. The stock opened at Rs 13.49, moved between a day low of Rs 13.45 and a day high of Rs 14.95, and traded very close to the intraday peak by the time this Univest article was generated at 10 August 2026 at 1:16:39 PM IST. The event itself was flagged at 10 August 2026 at 1:16:37 PM IST, showing that the price rise had already crossed the qualifying screen during live market hours.

Volume also put Syncom Formulations Stock News on the radar. BSE volume stood at 5,13,283 shares, NSE volume at 82,85,605 shares and total traded volume at 87,98,888 shares. Even though the workflow identifies BSE as the volume exchange for this trigger, the broader consolidated activity shows the stock was actively traded across exchanges. For readers of Univest looking for Syncom Formulations Share News, the key takeaway is simple: a double-digit price rise, heavy turnover and a market-cap-relevant move made the stock one of the names worth monitoring in Stock Market Today.

Syncom Formulations (India) Ltd. (SYNCOMF) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 14.89
Previous Close	Rs 13.44
Today's Change	+Rs 1.45 (+10.79%)
Day Open	Rs 13.49
Day High	Rs 14.95
Day Low	Rs 13.45
Current Volume (BSE)	5,13,283
BSE Traded Volume	5,13,283
NSE Traded Volume	82,85,605
Combined NSE + BSE Volume	87,98,888
Turnover	Rs 0.76 crore
Market Capitalisation	Rs 1,263.36 crore
Market Cap Category	Small Cap

Syncom Formulations (India) Ltd. (SYNCOMF) traded at Rs 14.89. versus the previous close of Rs 13.44, a rise of 10.79%. The stock opened at Rs 13.49, reached Rs 14.95, touched Rs 13.45. Reported volume was 5,13,283.

Syncom Formulations (India) Ltd. (SYNCOMF) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 1,263.36 crore
P/E Ratio	16.53x
P/B Ratio	3.04x
ROE	18.04%
ROCE	20.72%
EPS	Rs 0.81
Dividend Yield	0%

Syncom Formulations (India) Ltd. was valued at a P/E ratio of 16.53x, a P/B ratio of 3.04x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 18.04% and ROCE of 20.72%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 0.81, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Syncom Formulations Share Price is drawing attention, but the underlying valuation and profitability data provide useful balance. At a market capitalisation of Rs 1,263.36 crore, the company is a small-cap name rather than a large diversified pharma major, so the stock’s movements can attract stronger investor focus during active sessions. The supplied P/E ratio is 16.53 and the P/B ratio is 3.04, giving two important anchors for Syncom Formulations Fundamental Analysis.

On profitability, return ratios are notable. ROE stands at 18.04%, while ROCE is 20.72%. Those figures matter because they indicate the company has been generating a double-digit return both on shareholder equity and on capital employed. EPS is Rs 0.81, which gives the earnings attributable to each share based on the supplied data. Dividend yield is 0, meaning the current dataset does not point to a cash yield component in the stock at this price level. That keeps the focus firmly on earnings, capital efficiency and price action rather than on income distribution.

From a valuation perspective, Syncom Formulations Share Price does not look stretched solely on the basis of the sector benchmark supplied. Its P/E of 16.53 is below the same-industry median of 26.3 and well below the average of 80.76 across 104 companies with available P/E data in Pharmaceuticals & Drugs. By contrast, the P/B of 3.04 is above the industry median of 1.83 and slightly above the average of 2.92 across 139 companies. That combination suggests a stock that is cheaper than many peers on earnings, but not obviously cheap on book value.

The return ratios strengthen the investment context behind today’s move. Company ROE of 18.04% is above both the industry median of 9.93% and average of 7.45%. Company ROCE of 20.72% is also above the industry median of 12.96% and average of 14.33%. For readers of Univest following Syncom Formulations Earnings and company financials, that means the share price rise is occurring in a stock with profitability metrics that compare favourably with its wider listed industry set. That does not amount to a recommendation, but it does explain why the stock merits closer tracking after a strong day.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	16.53x
Benchmark Median P/E	26.3x
Benchmark Average P/E	80.76x
Benchmark P/E Range	3.21x to 3,417.8x
Company P/B Ratio	3.04x
Benchmark Median P/B	1.83x
Company ROE	18.04%
Benchmark Median ROE	9.93%
Company ROCE	20.72%
Benchmark Median ROCE	12.96%
Company Market Capitalisation	Rs 1,263.36 crore
Benchmark Median Market Cap	Rs 142.44 crore

Syncom Formulations (India) Ltd. (SYNCOMF) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Syncom Formulations (India) Ltd. (SYNCOMF) has a P/E ratio of 16.53x, which is below the benchmark median of 26.3x, a difference of -37.15%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Syncom Formulations (India) Ltd. (SYNCOMF) has a ROE of 18.04%, which is above the benchmark median of 9.93%, a difference of +81.67%. Syncom Formulations (India) Ltd. (SYNCOMF) has a ROCE of 20.72%, which is above the benchmark median of 12.96%, a difference of +59.88%.

Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Syncom Formulations Share Price is best understood within its Healthcare sector and Pharmaceuticals & Drugs industry setting. The benchmark in the supplied dataset covers the same industry, spans 140 companies and allows a direct comparison of valuation, profitability and market-cap position rather than relying on broad market assumptions.

Starting with size, Syncom Formulations has a market capitalisation of Rs 1,263.36 crore. That is far above the industry median market cap of Rs 142.44 crore and above the average of Rs 489.44 crore. Within the benchmark range, the smallest company stands at Rs 2.09 crore and the largest at Rs 3,032.97 crore. So, while the stock is classified as Small Cap in the market-cap screening framework, it is still meaningfully larger than the typical listed company in this particular industry group.

Valuation presents a mixed but informative picture. The company’s P/E ratio of 16.53 sits below the industry median of 26.3, below the average of 80.76, and well within a broad range of 3.21 to 3,417.8 across 104 companies with available P/E data. On this measure, Syncom Formulations Share Price appears less demanding than much of the industry set. However, the P/B ratio of 3.04 is above the benchmark median of 1.83 and slightly above the average of 2.92 across 139 companies, placing the stock closer to the richer side of the book-value range, which runs from -16 to 59.75.

Profitability metrics are a clearer relative positive. Company ROE of 18.04% is stronger than the industry median of 9.93% and the average of 7.45%. Company ROCE of 20.72% is also ahead of the industry median of 12.96% and average of 14.33%. For investors using Univest for Sector Analysis and Financial Analysis, that combination is important: Syncom Formulations Share Price is rising in a stock that trades below industry median P/E while delivering above-benchmark ROE and ROCE. That is a more nuanced setup than a price move alone might suggest.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	3,032.97	31.12	0.45	-2.89	-0.26
Hikal Ltd.	HIKAL	2,799.54	0	2.35	15.22	16.15
Kwality Pharmaceuticals Ltd.	KPL	2,707.2	40.2	8.18	28.21	26.35
Beta Drugs Ltd.	BETA	2,631.45	63.43	6.27	18.65	22.17
Panacea Biotec Ltd.	PANACEABIO	2,531.49	0	3.03	0	5.36

Syncom Formulations (India) Ltd. (SYNCOMF) has a P/E ratio of 16.53x compared with the displayed peer median of 31.12x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 18.04% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 20.72% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Syncom Formulations (India) Ltd. (SYNCOMF) has a market capitalisation of Rs 1,263.36 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Syncom Formulations Share Price also stands out when compared with listed peers in Pharmaceuticals & Drugs. The supplied peer set includes companies such as Dishman Carbogen Amcis, Hikal, Kwality Pharmaceuticals, Beta Drugs, Panacea Biotec, Sai Parenteral’s, Solara Active Pharma Sciences, NGL Fine-Chem, Venus Remedies and Hester Biosciences.

On market capitalisation, Syncom Formulations at Rs 1,263.36 crore is smaller than all ten named peers in the supplied list, where the range starts at Hester Biosciences with Rs 2,057.85 crore and goes up to Dishman Carbogen Amcis at Rs 3,032.97 crore. That smaller size can matter because moves in Small Cap stocks often draw higher attention in Share Market Today when price momentum develops.

On valuation, the company’s P/E of 16.53 is below Dishman Carbogen Amcis at 31.12, Kwality Pharmaceuticals at 40.2, Beta Drugs at 63.43, Sai Parenteral’s at 176.28 and NGL Fine-Chem at 44.02. It is also below Venus Remedies at 17.81, though slightly above Hester Biosciences at 15.11. Hikal, Panacea Biotec and Solara Active Pharma Sciences do not have P/E values shown in the supplied peer set, so the direct earnings-multiple comparison is naturally concentrated among the available figures.

Profitability is respectable relative to peers. Syncom Formulations ROE of 18.04% is stronger than Hikal’s 15.22%, Panacea Biotec’s 0, Sai Parenteral’s 13.9%, Solara’s 17.23%, Venus Remedies’ 9.85%, Hester Biosciences’ 16.17% and Dishman Carbogen Amcis’ -2.89%. It is slightly below Beta Drugs at 18.65% and well below Kwality Pharmaceuticals at 28.21% and NGL Fine-Chem at 27.9%. On ROCE, Syncom Formulations at 20.72% beats Hikal at 16.15%, Panacea Biotec at 5.36%, Sai Parenteral’s at 12.97%, Solara at 15.34%, Venus Remedies at 7.89%, Hester Biosciences at 14.12% and Dishman Carbogen Amcis at -0.26%, while remaining below Beta Drugs at 22.17%, Kwality Pharmaceuticals at 26.35% and NGL Fine-Chem at 33.91%.

For Syncom Formulations Stock Analysis, the peer picture is therefore balanced: smaller in size, lower on P/E than many peers, and competitive on ROE and ROCE against a meaningful part of the industry set.

Why Investors Are Watching Syncom Formulations

Syncom Formulations Share Price has moved into focus because today’s move combines a double-digit gain, active trading participation and a valuation-profitability profile that looks more interesting once the sector numbers are laid alongside the company data. In Market Movers today, that mix often matters more than a price rise alone.

• Verified price action: the stock rose 10.79% to Rs 14.89 from Rs 13.44, after opening at Rs 13.49 and touching Rs 14.95.
• Trading participation: total volume reached 87,98,888 shares, including 5,13,283 shares on BSE and 82,85,605 shares on NSE.
• Category relevance: with market capitalisation at Rs 1,263.36 crore, the stock falls in the Small Cap bracket and cleared the day’s qualifying price-rise bar for that screen.
• Fundamental context: P/E is 16.53, P/B is 3.04, ROE is 18.04%, ROCE is 20.72% and EPS is Rs 0.81.
• Sector positioning: P/E is below the industry median, while ROE and ROCE are above the same-industry median and average benchmarks.

What investors may monitor next is whether Syncom Formulations Share Price continues to hold near the day’s upper band, whether turnover remains elevated after today’s move, and how the stock’s valuation continues to compare with Healthcare and Pharmaceuticals & Drugs peers. As Univest notes, the data confirms the price event clearly, even though it does not identify a specific company-level catalyst.

About Syncom Formulations

Syncom Formulations (India) Ltd. is positioned within the Healthcare sector and the Pharmaceuticals & Drugs industry. Even with limited descriptive corporate detail in the supplied dataset, that classification itself is informative because it places the company in a segment where investors frequently compare valuation, capital efficiency and scale across a wide listed universe.

The industry benchmark used here covers 140 companies in the same Pharmaceuticals & Drugs space, which indicates that Syncom Formulations operates in a competitive and diverse listed environment. The market-cap data also provides perspective on its standing. At Rs 1,263.36 crore, the company is larger than the median and average company in this benchmark set, though still smaller than several directly named peers such as Dishman Carbogen Amcis, Hikal, Kwality Pharmaceuticals, Beta Drugs and Panacea Biotec.

For readers searching Syncom Formulations Company News or Syncom Formulations Latest News, the most reliable company overview from the current dataset is this: it is a listed pharma-sector business whose current market profile combines a Small Cap market classification with profitability ratios that compare favourably against many industry benchmarks. In practical terms, that means the market is not only reacting to a one-day move in the share price but also to a company that sits in an established listed industry where P/E, P/B, ROE and ROCE are widely watched metrics.

Track Syncom Formulations Share Price on Univest

Use Syncom Formulations (India) Ltd. (SYNCOMF) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors who want to follow Syncom Formulations Share Price more closely can use Univest to track live share price moves, daily highs and lows, market capitalisation, valuation ratios and profitability indicators in one place. For users comparing Syncom Formulations Share Price Today with sector peers, Univest also helps contextualise P/E, P/B, ROE, ROCE and 52-week levels alongside broader market insights.

Because Syncom Formulations Share Price is now part of Top Gainers Today, ongoing tracking matters not just for price action but also for understanding how the stock’s Market Cap, peer positioning and sector context evolve after a threshold-clearing session. Univest is particularly useful for watching structured Stock Updates without turning a market move into a prediction.

Frequently Asked Questions

Why did Syncom Formulations Share Price rise today?

Ans. Syncom Formulations Share Price rose because the stock moved 10.79% higher to Rs 14.89 from the previous close of Rs 13.44. The supplied data confirms the price event and high trading activity, but it does not establish a specific company-level.

What was Syncom Formulations Share Price Today?

Ans. Syncom Formulations Share Price Today was Rs 14.89 at the time of the article. The stock opened at Rs 13.49, touched a high of Rs 14.95, a low of Rs 13.45, and remained close to the day’s upper range.

How much did Syncom Formulations stock gain in today’s session?

Ans. The stock gained Rs 1.45 in absolute terms and 10.79% in percentage terms during the session. That move was strong enough to place Syncom Formulations among the notable small-cap gainers identified by the screening event.

What is the market capitalisation of Syncom Formulations?

Ans. Syncom Formulations had a market capitalisation of Rs 1,263.36 crore in the supplied dataset. That places it in the Small Cap category, while still making it larger than the median company in its Pharmaceuticals & Drugs benchmark set.

How active was trading in Syncom Formulations today?

Ans. Trading activity was elevated, with total volume of 87,98,888 shares. BSE volume stood at 5,13,283 shares, NSE volume was 82,85,605 shares, and BSE turnover for the trigger snapshot was Rs 0.76 crore.

Is Syncom Formulations expensive based on P/E ratio?

Ans. Syncom Formulations trades at a P/E of 16.53, which is below the same-industry median of 26.3 and far below the average of 80.76. On earnings multiple alone, the stock looks less demanding than much of the benchmark universe.

How does Syncom Formulations compare on profitability?

Ans. The company’s ROE is 18.04% and ROCE is 20.72%. Both figures are above the industry median levels of 9.93% and 12.96%, respectively, indicating stronger reported capital efficiency than many peers in the benchmark set.

What does the P/B ratio say about Syncom Formulations?

Ans. Syncom Formulations has a P/B ratio of 3.04. That is above the industry median of 1.83 and slightly above the average of 2.92, suggesting the stock is not especially cheap when judged against book value.

Does Syncom Formulations pay a dividend?

Ans. The supplied data shows a dividend yield of 0 for Syncom Formulations. That means the current market view in this dataset is centred more on earnings, valuation and price action than on historical dividend income.

What should investors monitor after today’s move in Syncom Formulations?

Ans. Investors can monitor whether Syncom Formulations holds near today’s upper trading band, whether strong volume participation continues, and how its P/E, P/B, ROE and ROCE compare with Pharmaceuticals & Drugs peers after this 10.79% rise.